Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents

The objective is to analyze the predictive impact of circulating MMP2 and MMP9 on the progression-free survival of patients with metastatic kidney cancer treated with anti-angiogenic agents (Sunitinib or Pazopanib) in comparison with two untreated cohorts (localized or oligometastatic cancer).

Prospective monocenter, open-label study

In the frame of disease management blood samples will be collected at different times of follow-up regarding disease status (localized, oligometastatic and metastatic) and tissue samples will be collected for patients scheduled for surgery.

Inclusion criteria

• Patient male or female, aged of more than 18 years
• Patient with any of the following conditions:

• Kidney cancer localized at diagnosis.
• Metastatic kidney cancer when anti-angiogenic therapy is initiated by Sunitinib or Pazopanib
• Oligometastatic kidney cancer without systemic treatment (local treatment)
• ECOG = 0 to 2
• Patient affiliated to, or beneficiary of, the national social security.
• Patient having signed informed consent

Exclusion criteria

• Patient previously treated with anti-angiogenic agents.
• Person in an emergency situation, adult subject to a legal protection measure (a guardian, guardianship or safeguard of justice), or unable of expressing his / her consent.
• Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons 4. History of malignant disease in the 5 years prior to inclusion (except basal cell carcinoma of the skin or epithelioma of the cervix in situ, or prostate cancer with a good prognosis (stage T <3 and Gleason <7)) accidentally discovered during the histological analysis of the tumor sample.

5- Pregnant or nursing women 6- Contraindications to the procedure of the study